focus -WSS

focus

author：focus 2025-09-30 17:28:21 - browse：87198

Humana sign -- health business coverage from STAT — Humana’s Medicare Advantage business is faring even worse than the company let on last week. Ed Reinke/AP

Humana’s Medicare Advantage business is faring even worse than the company let on last week, with “unprecedented” numbers of older adults getting medical care and busting through its tactics for holding up payment.

The country’s second largest private Medicare insurer disclosed Thursday it’s projecting roughly half the profit in 2024 that investors had expected. The news comes a week after Humana already lowered its projected 2023 profit, which still came in at north of $3 billion before taxes.

The stock market’s punishment was swift and decisive, sinking Humana’s share price by roughly 12% at midday. Outgoing CEO Bruce Broussard worked to calm nerves on the company’s investor call, reiterating his confidence in MA. Humana went all-in on the program when it announced last year it would wind down its employer business, but that comes as regulators are beefing up scrutiny of MA plans.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

WSS

What health policies could hitch a ride on a spending bill?

Senate panel puts off hardest PBM reforms for another day

Dems pitch expanding Medicare power to negotiate drug prices

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

STAT Report: Patient voices and perspectives

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

knowledge

focus

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

A letter from the executive editor: STAT UnitedHealth investigation

Heart attack and stroke risk calculators need revising

What health policies could hitch a ride on a spending bill?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Study suggests Covid rebound is far more common with Paxlovid than without

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Study suggests Covid rebound is far more common with Paxlovid than without

Guidelines to prevent youth baseball injuries need more muscle

CVS, Rite Aid closures threaten to worsen pharmacy deserts

focus

Truvian presents data for its desktop blood

Type 2 diabetes prevention programs work at large scale: study

A new crop of companies is reshaping the health data economy

NIH chief: government has fallen behind pharma on clinical trials

Senate panel puts off hardest PBM reforms for another day

Will the FTC rein in IQVIA's health data empire?

hotspot

entertainment

hotspot

hotspot